UT Research Foundation licensee Veru, Inc. announced on April 11, 2022, that their Phase 3 clinical trial of sabizabulin as an oral therapy for hospitalized severe COVID-19 patients at high risk for Acute Respiratory Distress Syndrome (ARDS) and death showed the drug to be safe and effective. The trial was halted early due to the (read more)
UTHSC
UT pharmacy students developing device to individualize the smoking cessation process
Smoking is one of the most prominent causes of preventable disease each year in the United States. According to the 2020 National Survey on Drug Use and Health, 57.3 million people reported tobacco or nicotine vaping use in the past month. Meanwhile, a 2017 study of smokers from the Centers for Disease Control and Prevention (read more)
Inventor Spotlight: Dr. Harry Kochat
Plough Center Director dedicated to safely transitioning innovative drug discoveries out of the lab and to patients who need them In 2012, over 700 patients across 20 states received tainted steroid injections, resulting in 64 deaths. Tennessee had 153 of these cases and 16 deaths. This multi-state outbreak of fungal meningitis and other infections emphasized (read more)